|
|
Volumn 88, Issue 3, 2000, Pages 469-473
|
|
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
6 O METHYLGUANINE;
DNA;
METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;
TEMOZOLOMIDE;
ALKYLATING AGENT;
DACARBAZINE;
DRUG DERIVATIVE;
GUANINE;
O (6) METHYLGUANINE;
O-(6)-METHYLGUANINE;
ADULT;
AGED;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
BONE MARROW SUPPRESSION;
CANCER STAGING;
CLINICAL ARTICLE;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG RESPONSE;
ENZYME BLOOD LEVEL;
FEMALE;
FEVER;
HUMAN;
HUMAN TISSUE;
KINETICS;
LYMPHOCYTE;
MALE;
MELANOMA;
MONONUCLEAR CELL;
NEUTROPENIA;
PHASE 2 CLINICAL TRIAL;
PRIORITY JOURNAL;
PROTEIN DEPLETION;
SURVIVAL RATE;
THROMBOCYTOPENIA;
TUMOR BIOPSY;
BIOSYNTHESIS;
DRUG ADMINISTRATION;
METABOLISM;
MIDDLE AGED;
MORTALITY;
ADULT;
AGED;
AGED, 80 AND OVER;
ANTINEOPLASTIC AGENTS, ALKYLATING;
DACARBAZINE;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
GUANINE;
HUMANS;
MALE;
MELANOMA;
MIDDLE AGED;
O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE;
|
|
EID: 0033623440
PISSN: 00207136
EISSN: None
Source Type: Journal
DOI: 10.1002/1097-0215(20001101)88:3<469::AID-IJC21>3.0.CO;2-7 Document Type: Article |
|
Times cited : (65)
|
|
References (27)
|
